Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-08-13 Regulatory Filings
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
SCHEDULE 13D/A-GeneDx Holdings, Corp
Regulatory Filings Classification · 95% confidence The document explicitly mentions 'SCHEDULE 13D/A' and references the 'Israel Securities Authority' and 'Tel Aviv Stock Exchange'. Schedule 13D/A is a filing used in the US to report beneficial ownership of more than 5% of a class of a company's securities, and the '/A' indicates an amendment. While this is a US SEC filing type, the context here is a foreign corporation reporting via the Israeli regulatory system (MAGNA). Schedule 13D filings relate to significant share ownership changes, which aligns closely with the definition of 'Major Shareholding Notification' (MRQ). However, since this is a specific regulatory filing (Schedule 13D/A) that doesn't perfectly match the defined categories (like 10-K, ER, etc.), and it is a direct regulatory report rather than an announcement of a report (the document text is the report content itself, not just a link), the most appropriate classification among the provided options that covers significant ownership changes is MRQ. If MRQ was not available, RNS would be the fallback. Given the content is a direct filing amendment regarding ownership, MRQ is the best fit.
2024-08-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing Classification · 100% confidence The document explicitly contains the header '| FORM 4 |' and references filing pursuant to 'Section 16(a) of the Securities Exchange Act of 1934'. Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the provided definitions: - 10-K: Annual Report (Incorrect). - ER: Earnings Release (Incorrect). - DEF 14A: Remuneration Information (Incorrect). - DIRS: Director's Dealing (Report of personal share transactions by company directors and executives (insider trades)). This is the correct classification for an SEC Form 4 filing. Therefore, the filing type is DIRS.
2024-08-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is 'Attached hereto is a report on *interested party transaction* *20240809Form4_isa.pdf*'. This structure—a brief regulatory filing announcing the attachment of a specific report (in this case, related to an interested party transaction, which often falls under insider/related-party disclosures)—indicates that this document is primarily an announcement of the attached report rather than the full report itself. Since the content is a notification about a specific transaction disclosure, and it is not a standard 10-K, ER, or IR, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, specific regulatory announcement, or potentially related to insider/related-party dealings, though RNS is the safest general regulatory fallback for non-standard disclosures.
2024-08-09 English
Form 10-Q- For the quarterly period ended June 30, 2024.
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'FORM 10-Q' and identifies itself as a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934'. It contains comprehensive financial statements, notes, and management discussion for the period ended June 30, 2024. While the filing category '10-K' is often used for annual reports, the provided schema lists '10-K' as the code for annual reports and 'IR' for interim/quarterly reports. Therefore, 'IR' is the correct classification for a 10-Q. Q2 2024
2024-08-07 English
Form 10-Q- For the quarterly period ended June 30, 2024.
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli Securities Authority regulations. Crucially, it mentions an attached report: 'Attached hereto is a report on *Form 10-Q ������ ������ ������ 2, 2024*'. A Form 10-Q is the standard SEC filing for quarterly financial reports, which corresponds to the definition of an Interim/Quarterly Report (IR). However, the document itself is very short (1869 chars) and functions as an announcement stating that the 10-Q is attached or linked, rather than being the full 10-Q content. According to Rule 2, when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). Since this document is announcing the release of a Form 10-Q (an Interim Report), RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2024-08-07 English
Form 8-K-Second Quarter 2024 Business Highlights and Financial Results
Earnings Release Classification · 99% confidence The document explicitly identifies itself as a "FORM 8-K" and a "CURRENT REPORT" filed with the SEC. Item 2.02 specifically references the announcement of operating and financial highlights for the quarter ended June 30, 2024, via a press release (Exhibit 99.1). This structure—a Form 8-K used to report material, current events, often including the release of quarterly earnings highlights—is characteristic of an Earnings Release (ER) being filed under the 8-K framework. While it contains financial details, the primary purpose of the 8-K filing itself, in this context, is to report the release of the earnings information. However, the provided definitions do not have a specific code for Form 8-K reporting earnings. The closest fit for the *content* being reported (quarterly financial results and highlights) is 'ER' (Earnings Release). Since the document is a full SEC filing (Form 8-K) and not just the press release itself, and it contains detailed financial data, it is more substantial than a simple RPA. Given the options, 'ER' captures the core subject matter (quarterly results announcement), but 'RNS' (Regulatory Filings) is the most accurate code for a Form 8-K filing that isn't a 10-K or IR. Since the content is clearly an earnings announcement, and ER is available, I will prioritize the content type over the generic filing type, as the document *is* the earnings announcement filed via 8-K. The document is substantial (over 25k characters) and contains the full results, making it more than just an announcement of a report (RPA). It is the official filing of the earnings information. Q2 2024
2024-08-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.